BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Therapeutics (TPST)Tempest TherapeuticsCompany update

All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027 Operational runway extended to mid-2027, supporting multiple potential

Related news

TPSTTempest Therapeutics2026-07-21 11:00 EST

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

TPSTTempest Therapeutics2026-07-15 11:00 EST

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

LEGNLegend Biotech Corporation2026-06-15 12:00 EST

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GSKGSK plc2026-07-15 13:40 EST

GSK completes acquisition of Nuvalent, Inc.

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

SNDXSyndax Pharmaceuticals2026-07-14 12:00 EST

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

TEVATeva Pharmaceutical Industries2026-06-10 16:03 EST

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

View all latest news

Tempest Therapeutics

In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells...

Recent company news

TPSTTempest Therapeutics2026-08-13 20:26 EST

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-07-21 11:00 EST

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

TPSTTempest Therapeutics2026-07-15 11:00 EST

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

TPSTTempest Therapeutics2026-06-04 20:37 EST

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Stock data

Close
1.04 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States